Cargando…

Antibody Persistence 6 Months Post-Vaccination with BNT162b2 among Health Care Workers

Background: We present immunogenicity data 6 months after the first dose of BNT162b2 in correlation with age, gender, BMI, comorbidities and previous SARS-CoV-2 infection. Methods: An immunogenicity evaluation was carried out among health care workers (HCW) vaccinated at the Istituti Fisioterapici O...

Descripción completa

Detalles Bibliográficos
Autores principales: Campo, Flaminia, Venuti, Aldo, Pimpinelli, Fulvia, Abril, Elva, Blandino, Giovanni, Conti, Laura, De Virgilio, Armando, De Marco, Federico, Di Noia, Vincenzo, Di Domenico, Enea Gino, Di Martino, Simona, Ensoli, Fabrizio, Giannarelli, Diana, Mandoj, Chiara, Mazzola, Francesco, Moretto, Silvia, Petruzzi, Gerardo, Petrone, Fabrizio, Pichi, Barbara, Pontone, Martina, Vidiri, Antonello, Vujovic, Branka, Piaggio, Giulia, Sperandio, Eleonora, Rosati, Valentina, Cognetti, Francesco, Morrone, Aldo, Ciliberto, Gennaro, Pellini, Raul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8538824/
https://www.ncbi.nlm.nih.gov/pubmed/34696233
http://dx.doi.org/10.3390/vaccines9101125
_version_ 1784588599255105536
author Campo, Flaminia
Venuti, Aldo
Pimpinelli, Fulvia
Abril, Elva
Blandino, Giovanni
Conti, Laura
De Virgilio, Armando
De Marco, Federico
Di Noia, Vincenzo
Di Domenico, Enea Gino
Di Martino, Simona
Ensoli, Fabrizio
Giannarelli, Diana
Mandoj, Chiara
Mazzola, Francesco
Moretto, Silvia
Petruzzi, Gerardo
Petrone, Fabrizio
Pichi, Barbara
Pontone, Martina
Vidiri, Antonello
Vujovic, Branka
Piaggio, Giulia
Sperandio, Eleonora
Rosati, Valentina
Cognetti, Francesco
Morrone, Aldo
Ciliberto, Gennaro
Pellini, Raul
author_facet Campo, Flaminia
Venuti, Aldo
Pimpinelli, Fulvia
Abril, Elva
Blandino, Giovanni
Conti, Laura
De Virgilio, Armando
De Marco, Federico
Di Noia, Vincenzo
Di Domenico, Enea Gino
Di Martino, Simona
Ensoli, Fabrizio
Giannarelli, Diana
Mandoj, Chiara
Mazzola, Francesco
Moretto, Silvia
Petruzzi, Gerardo
Petrone, Fabrizio
Pichi, Barbara
Pontone, Martina
Vidiri, Antonello
Vujovic, Branka
Piaggio, Giulia
Sperandio, Eleonora
Rosati, Valentina
Cognetti, Francesco
Morrone, Aldo
Ciliberto, Gennaro
Pellini, Raul
author_sort Campo, Flaminia
collection PubMed
description Background: We present immunogenicity data 6 months after the first dose of BNT162b2 in correlation with age, gender, BMI, comorbidities and previous SARS-CoV-2 infection. Methods: An immunogenicity evaluation was carried out among health care workers (HCW) vaccinated at the Istituti Fisioterapici Ospitalieri (IFO). All HCW were asked to be vaccine by the national vaccine campaign at the beginning of 2021. Serum samples were collected on day 1 just prior to the first dose of the vaccine and on day 21 just prior to the second vaccination dose. Thereafter sera samples were collected 28, 49, 84 and 168 days after the first dose of BNT162b2. Quantitative measurement of IgG antibodies against S1/S2 antigens of SARS-CoV-2 was performed with a commercial chemiluminescent immunoassay. Results: Two hundred seventy-four HWCs were analyzed, 175 women (63.9%) and 99 men (36.1%). The maximum antibody geometric mean concentration (AbGMC) was reached at T2 (299.89 AU/mL; 95% CI: 263.53–339.52) with a significant increase compared to baseline (p < 0.0001). Thereafter, a progressive decrease was observed. At T5, a median decrease of 59.6% in COVID-19 negative, and of 67.8% in COVID-19 positive individuals were identified with respect to the highest antibody response. At T1, age and previous COVID-19 were associated with differences in antibody response, while at T2 and T3 differences in immune response were associated with age, gender and previous COVID-19. At T4 and T5, only COVID-19 positive participants demonstrated a greater antibody response, whereas no other variables seemed to influence antibody levels. Conclusions: Overall our study clearly shows antibody persistence at 6 months, albeit with a certain decline. Thus, the use of this vaccine in addressing the COVID-19 pandemic is supported by our results that in turn open debate about the need for further boosts.
format Online
Article
Text
id pubmed-8538824
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85388242021-10-24 Antibody Persistence 6 Months Post-Vaccination with BNT162b2 among Health Care Workers Campo, Flaminia Venuti, Aldo Pimpinelli, Fulvia Abril, Elva Blandino, Giovanni Conti, Laura De Virgilio, Armando De Marco, Federico Di Noia, Vincenzo Di Domenico, Enea Gino Di Martino, Simona Ensoli, Fabrizio Giannarelli, Diana Mandoj, Chiara Mazzola, Francesco Moretto, Silvia Petruzzi, Gerardo Petrone, Fabrizio Pichi, Barbara Pontone, Martina Vidiri, Antonello Vujovic, Branka Piaggio, Giulia Sperandio, Eleonora Rosati, Valentina Cognetti, Francesco Morrone, Aldo Ciliberto, Gennaro Pellini, Raul Vaccines (Basel) Brief Report Background: We present immunogenicity data 6 months after the first dose of BNT162b2 in correlation with age, gender, BMI, comorbidities and previous SARS-CoV-2 infection. Methods: An immunogenicity evaluation was carried out among health care workers (HCW) vaccinated at the Istituti Fisioterapici Ospitalieri (IFO). All HCW were asked to be vaccine by the national vaccine campaign at the beginning of 2021. Serum samples were collected on day 1 just prior to the first dose of the vaccine and on day 21 just prior to the second vaccination dose. Thereafter sera samples were collected 28, 49, 84 and 168 days after the first dose of BNT162b2. Quantitative measurement of IgG antibodies against S1/S2 antigens of SARS-CoV-2 was performed with a commercial chemiluminescent immunoassay. Results: Two hundred seventy-four HWCs were analyzed, 175 women (63.9%) and 99 men (36.1%). The maximum antibody geometric mean concentration (AbGMC) was reached at T2 (299.89 AU/mL; 95% CI: 263.53–339.52) with a significant increase compared to baseline (p < 0.0001). Thereafter, a progressive decrease was observed. At T5, a median decrease of 59.6% in COVID-19 negative, and of 67.8% in COVID-19 positive individuals were identified with respect to the highest antibody response. At T1, age and previous COVID-19 were associated with differences in antibody response, while at T2 and T3 differences in immune response were associated with age, gender and previous COVID-19. At T4 and T5, only COVID-19 positive participants demonstrated a greater antibody response, whereas no other variables seemed to influence antibody levels. Conclusions: Overall our study clearly shows antibody persistence at 6 months, albeit with a certain decline. Thus, the use of this vaccine in addressing the COVID-19 pandemic is supported by our results that in turn open debate about the need for further boosts. MDPI 2021-10-03 /pmc/articles/PMC8538824/ /pubmed/34696233 http://dx.doi.org/10.3390/vaccines9101125 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Campo, Flaminia
Venuti, Aldo
Pimpinelli, Fulvia
Abril, Elva
Blandino, Giovanni
Conti, Laura
De Virgilio, Armando
De Marco, Federico
Di Noia, Vincenzo
Di Domenico, Enea Gino
Di Martino, Simona
Ensoli, Fabrizio
Giannarelli, Diana
Mandoj, Chiara
Mazzola, Francesco
Moretto, Silvia
Petruzzi, Gerardo
Petrone, Fabrizio
Pichi, Barbara
Pontone, Martina
Vidiri, Antonello
Vujovic, Branka
Piaggio, Giulia
Sperandio, Eleonora
Rosati, Valentina
Cognetti, Francesco
Morrone, Aldo
Ciliberto, Gennaro
Pellini, Raul
Antibody Persistence 6 Months Post-Vaccination with BNT162b2 among Health Care Workers
title Antibody Persistence 6 Months Post-Vaccination with BNT162b2 among Health Care Workers
title_full Antibody Persistence 6 Months Post-Vaccination with BNT162b2 among Health Care Workers
title_fullStr Antibody Persistence 6 Months Post-Vaccination with BNT162b2 among Health Care Workers
title_full_unstemmed Antibody Persistence 6 Months Post-Vaccination with BNT162b2 among Health Care Workers
title_short Antibody Persistence 6 Months Post-Vaccination with BNT162b2 among Health Care Workers
title_sort antibody persistence 6 months post-vaccination with bnt162b2 among health care workers
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8538824/
https://www.ncbi.nlm.nih.gov/pubmed/34696233
http://dx.doi.org/10.3390/vaccines9101125
work_keys_str_mv AT campoflaminia antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers
AT venutialdo antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers
AT pimpinellifulvia antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers
AT abrilelva antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers
AT blandinogiovanni antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers
AT contilaura antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers
AT devirgilioarmando antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers
AT demarcofederico antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers
AT dinoiavincenzo antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers
AT didomenicoeneagino antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers
AT dimartinosimona antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers
AT ensolifabrizio antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers
AT giannarellidiana antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers
AT mandojchiara antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers
AT mazzolafrancesco antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers
AT morettosilvia antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers
AT petruzzigerardo antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers
AT petronefabrizio antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers
AT pichibarbara antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers
AT pontonemartina antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers
AT vidiriantonello antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers
AT vujovicbranka antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers
AT piaggiogiulia antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers
AT sperandioeleonora antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers
AT rosativalentina antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers
AT cognettifrancesco antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers
AT morronealdo antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers
AT cilibertogennaro antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers
AT pelliniraul antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers